First-ever covalent irreversible inhibition of a protease central to hepatitis C infection
WALTHAM, MA — November 28, 2010 — Avila Therapeutics, Inc., a biotechnology company developing novel targeted covalent drugs, has published research in Nature Chemical Biology demonstrating the first-ever selective irreversible inhibition of…